More adverse reactions with HPV, says study

7 September 2008

The estimated rate of anaphylaxis in young women after human papillomavirus vaccination was five to 20 times higher than that identified in comparable school-based vaccination programs, according to a study published in the Canadian Medical Association Journal.

In the study of 114,000 women, a team of Australian researchers found 12 suspected cases of anaphylaxis, and confirmed eight of these, in a 2007 vaccination program in New South Wales, Australia. The estimated rate of anaphylaxis following HPV vaccination was 2.6 per 100,000 doses administered compared with a rate 0.1 per 100,000 doses administered in a 2003 school-based meningococcal C vaccination program. However, the overall rates of anaphylaxis were low with no associated serious, lasting effects. Symptoms included difficulty breathing, nausea and rashes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight